title: Non-Hodgkin lymphoma following temozolomide.
abstract: Temozolomide (TMZ) is an oral alkylating agent with significant activity against glioblastoma multiforme (GBM) and melanoma. It increases survival by 2.5 months when used in combination with radiotherapy as an adjuvant therapy in GBM. Secondary MDS/AML or non-Hodgkin lymphoma attributed to TMZ exposure has been reported. We report a case of non-Hodgkin lymphoma secondary to temozolomide in a 20-year-old female who was treated for GBM with concurrent TMZ and radiotherapy. She developed lymphoma 2 months after completing chemoradiotherapy. Although she was treated with combination chemotherapy for lymphoma, she died of progressive GBM.
authors.affiliation: Department of Medical Oncology, Dr BRA Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India. atul1@hotmail.com
authors.forename: Atul
authors.initials: A
authors.lastname: Sharma
authors.forename: Deepak
authors.initials: D
authors.lastname: Gupta
authors.forename: B K
authors.initials: BK
authors.lastname: Mohanti
authors.forename: Sanjay
authors.initials: S
authors.lastname: Thulkar
authors.forename: Amit
authors.initials: A
authors.lastname: Dwary
authors.forename: Shikha
authors.initials: S
authors.lastname: Goyal
authors.forename: Sandeep
authors.initials: S
authors.lastname: Muzumder
authors.forename: Prasenjit
authors.initials: P
authors.lastname: Das
mesh_terms: D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000139:chemically induced*; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide